Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer ; volume:7 ; number:1 ; day:9 ; month:4 ; year:2014 ; pages:1-11 ; date:12.2014
Journal of ovarian research ; 7, Heft 1 (9.4.2014), 1-11, 12.2014
- Creator
-
Kawaguchi, Hiroshi
Terai, Yoshito
Tanabe, Akiko
Sasaki, Hiroshi
Takai, Masaaki
Fujiwara, Satoe
Ashihara, Keisuke
Tanaka, Yoshimichi
Tanaka, Tomohito
Tsunetoh, Satoshi
Kanemura, Masanori
Ohmichi, Masahide
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1757-2215-7-38
- URN
-
urn:nbn:de:101:1-2021082208572842700776
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kawaguchi, Hiroshi
- Terai, Yoshito
- Tanabe, Akiko
- Sasaki, Hiroshi
- Takai, Masaaki
- Fujiwara, Satoe
- Ashihara, Keisuke
- Tanaka, Yoshimichi
- Tanaka, Tomohito
- Tsunetoh, Satoshi
- Kanemura, Masanori
- Ohmichi, Masahide
- SpringerLink (Online service)
Other Objects (12)
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer
Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer
Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer
New Platinum(II) Complexes Affecting Different Biomolecular Targets in Resistant Ovarian Carcinoma Cells
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada